Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome
Yıl: 2021 Cilt: 59 Sayı: 1 Sayfa Aralığı: 74 - 79 Metin Dili: İngilizce DOI: 10.4274/haseki.galenos.2021.6788 İndeks Tarihi: 19-06-2021
Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome
Öz: Aim: Today, there are many risk calculation methods. In this study, we aimed to compare SCORE, QRISK2, BNF, ASSIGN and Framingham risk scorings for patients who have been first detected that they have hyperlipidemia and to evaluate the relation between metabolic syndrome criteria and cardiovascular risk scorings for the same group patients. Methods: We included 216 female, 84 male newly diagnosed hyperlipidemic patients. Lipid levels measured using enzymatic calorimetric methods. We also measured weight, height, waist circumference of patients. We used NCEP ATP III for metabolic syndrome identification. For 10 years cardiovascular risk assessment we performed Framingham, SCORE, QRISK 2, ASSIGN, BNF score systems. Results: The difference between these four different methods found statistically significant with Friedman test (p<0.001). With post-hoc dual analysis, we found that Framinghan score was different from the other 3 methods, QRISK2 score was different from Framingham and ASSIGN score results, ASSIGN score was different from other 3 score results and BNF score was also different from Framingham and ASSIGN score results. Only between BNF-QRISK2 scores we could not find difference.Conclusions: This study showed that when four different cardiovascular risk score methods are compared in newly diagnosed hyperlipidemia patients, only BNF and QRISK2 scorings revealed similar results but Framingham and ASSIGN scorings resulted differently either from each other or BNF and QRISK2
Anahtar Kelime: Yeni Tanı Almış Hiperlipidemili Hastalarda Farklı Kardiyovasküler Risk Skorlamalarının Karşılaştırılması ve Bunlarin Metabolik Sendromla İlişkileri
Öz: Amaç: Günümüzde çok sayıda kardiyovasküler risk hesaplama sistemi bulunmaktadır. Biz bu çalışmada ilk kez hiperlipidemi saptanan hastalarda SCORE, QRISK2, BNF, ASSIGN, Framingham risk skorlamalarını karşılaştırmayı ve aynı grup hastalarda metabolik sendrom kriterlerinin varlığı ile kardiyovasküler risk skorlamaları arasındaki ilişkiyi değerlendirmeyi amaçladık. Yöntemler: Yeni hiperlipidemi tanısı almış 216 kadın, 84 erkek hastayı çalışmaya dahil ettik. Kan lipid seviyeleri için enzimatik kalorimetrik yöntemler kullanıldı. Hastaların kilosu, boyu, bel çevresi de ölçüldü. Metabolik sendrom tanımlaması için NCEP ATP III kriterlerini kullandık. 10 yıllık kardiyovasküler risk değerlendirmesi için de Framingham, SCORE, QRISK 2, ASSIGN, BNF skor sistemleri uyguladık. Bulgular: Bu dört farklı yöntem arasındaki fark, Friedman testi ile istatistiksel olarak anlamlı bulundu (p<0,001). Post-hoc ikili analiz ile Framinghan skor sisteminin diğer 3 skor sisteminden, QRISK2 skor sisteminin Framingham ve ASSIGN skor sistemlerinden farklı olduğunu, ASSIGN skor sisteminin, diğer 3 skor sisteminden farklı olduğunu ve BNF skor sisteminin de Framingham ve ASSIGN’den farklı olduğunu bulduk. Sadece BNF ile QRISK2 skor sistemleri arasında fark bulamadık. Sonuç: Bu çalışma ile yeni tanı konmuş hiperlipidemili hastalarda dört farklı kardiyovasküler risk skorlama sistemi karşılaştırıldığında; sadece BNF ve QRISK2 skorlarının benzer sonuç verdiği ancak FRAMINGHAM ve ASSIGN skorlarının hem birbirinden hem de BNF ve QRISK2’den farklı sonuçlar verdiği ortaya konuldu.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:1376-414.
- 2.Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92.
- 3.Onat A, Albayrak S, Karabulut A. TEKHARF 2006. Available from: https://file.tkd.org.tr/PDFs/TEKHARF-2017.pdf Türk Kardiyoloji Dern Arş 2007;35:149-153.
- 4.Cupples LA, D’Agostino RB, Kiely D; The Framingham Study . An Epidemiological Investigation of Cardiovascular Disease, Section 34. Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements Framingham Heart Study, 30-Year Follow-Up. Bethesda, MD: National Heart, Lung, and Blood Institute; 1987.
- 5.Demir N, Yucelen SY, Cetin EG, et al. Determining INR Awareness of the Patients who Use Warfarin and Rates of Achieving the Target Dosage. Sisli Etfal Hastan Tip Bul 2020;54:357-63.
- 6.Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365:434-41.
- 7.Calim A, Turkoz FP, Ozturkmen YA, et al. The Relation between Homocysteine Levels in Patients with Acute Coronary Syndrome and Grace Score. Sisli Etfal Hastan Tip Bul 2020;54:346-50.
- 8.Şendur MAN, Güven GS. Metabolik Sendroma Güncel Bakış. Available from: http://ichastaliklaridergisi.org/managete/fu_folder/2011-03/html/2011-18-3-125-131.htm. İç Hastalıkları Dergisi 2011;18:125-131.
- 9.Lee GK, Lee LC, Liu CW, et al. Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction. Ann Acad Med Singap 2010;39:163-7.
- 10.Ghandehari H, Le V, Kamal-Bahl S, Bassin SL, Wong ND. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond) 2009;33:239-48.
- 11.Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin 2014;32:439-55.
- 12.Marsh RW. Predicting cardiovascular events using three stage Discriminant Function is much more accurate than Framingham or QRISK. Eur J Epidemiol 2011;26:915-8.
- 13.G B John Mancini, Arnold Ryomoto , Comparison of cardiovascular risk assessment algorithms to determine eligibility for statin therapy: implications for practice in Canada. Can J Cardiol. 2014 Jun;30(6):661-6.
- 14.Scheltens T, Verschuren WM, Boshuizen HC, et al. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. Eur J Cardiovasc Prev Rehabil 2008;15:562-6.
- 15.Simmonds MC, Wald NJ. Risk estimation versus screening performance: a comparison of six risk algorithms for cardiovascular disease. J Med Screen 2012;19:201-5.
| APA | Ilhan A, BASAT S, Demir N, Basat O, Altuntaş Y (2021). Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. , 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| Chicago | Ilhan Aysegul,BASAT SEMA,Demir Nazan,Basat Okcan,Altuntaş Yüksel Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. (2021): 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| MLA | Ilhan Aysegul,BASAT SEMA,Demir Nazan,Basat Okcan,Altuntaş Yüksel Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. , 2021, ss.74 - 79. 10.4274/haseki.galenos.2021.6788 |
| AMA | Ilhan A,BASAT S,Demir N,Basat O,Altuntaş Y Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. . 2021; 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| Vancouver | Ilhan A,BASAT S,Demir N,Basat O,Altuntaş Y Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. . 2021; 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| IEEE | Ilhan A,BASAT S,Demir N,Basat O,Altuntaş Y "Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome." , ss.74 - 79, 2021. 10.4274/haseki.galenos.2021.6788 |
| ISNAD | Ilhan, Aysegul vd. "Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome". (2021), 74-79. https://doi.org/10.4274/haseki.galenos.2021.6788 |
| APA | Ilhan A, BASAT S, Demir N, Basat O, Altuntaş Y (2021). Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. Haseki Tıp Bülteni, 59(1), 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| Chicago | Ilhan Aysegul,BASAT SEMA,Demir Nazan,Basat Okcan,Altuntaş Yüksel Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. Haseki Tıp Bülteni 59, no.1 (2021): 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| MLA | Ilhan Aysegul,BASAT SEMA,Demir Nazan,Basat Okcan,Altuntaş Yüksel Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. Haseki Tıp Bülteni, vol.59, no.1, 2021, ss.74 - 79. 10.4274/haseki.galenos.2021.6788 |
| AMA | Ilhan A,BASAT S,Demir N,Basat O,Altuntaş Y Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. Haseki Tıp Bülteni. 2021; 59(1): 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| Vancouver | Ilhan A,BASAT S,Demir N,Basat O,Altuntaş Y Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome. Haseki Tıp Bülteni. 2021; 59(1): 74 - 79. 10.4274/haseki.galenos.2021.6788 |
| IEEE | Ilhan A,BASAT S,Demir N,Basat O,Altuntaş Y "Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome." Haseki Tıp Bülteni, 59, ss.74 - 79, 2021. 10.4274/haseki.galenos.2021.6788 |
| ISNAD | Ilhan, Aysegul vd. "Comparisson of Different Cardiovascular Risk Scores in Newly Diagnosed Hyperlipidemia Patients and Their Relations with Metabolic Syndrome". Haseki Tıp Bülteni 59/1 (2021), 74-79. https://doi.org/10.4274/haseki.galenos.2021.6788 |
